Business
Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology
Quantitative analysis of medical claims indicates an estimated 44,553 to 92,967 diagnosed U.S. patients with lymphatic malformations (LMs) with cutaneous involvement Estimates of annual incidence of LMs with cutaneous involvement to be highlighted in the poster presentation Poster to be presented on Thursday, May 8, 2025, 4:30-6:00 pm PT WAYNE, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical compan
About this update from Palvella Therapeutics, Inc.
[{"type":"image","alt":"Palvella Therapeutics Inc.","displaySize":"","headline":null,"caption":"Palvella Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/4b273ae029a5e8cb06a3771e7b41e04d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IZ4VZ0Qdm50kE5TTbiIBBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4b273ae029a5e8cb06a3771e7b41e04d","width":300,"height":300}},"lazy":false},{"type":"text","content":"Quantitative analysis of medical claims indicates an estimated 44,553 to 92,967 diagnosed U.S. patients with lymphatic malformations (LMs) with cutaneous involvement","length":165,"tagName":"p"},{"type":"text","content":"Estimates of annual incidence of LMs with cutaneous involvement to be highlighted in the poster presentation","length":108,"tagName":"p"},{"type":"text","content":"Poster to be presented on Thursday, May 8, 2025, 4:30-6:00 pm PT","length":64,"tagName":"p"},{"type":"text","content":"WAYNE, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced an abstract highlighting the estimated diagnosed prevalence and annual incidence of lymphatic malformation (LM) cases in the U.S. was accepted for poster presentation at the Society for Investigative Dermatology (SID) Annual Meeting, taking place May 7-10, 2025, in San Diego, California.","length":692,"tagName":"p"},{"type":"text","content":"The abstract includes a medical claims-based analysis over a 7-year period conducted with data from Komodo Health. The analysis was aimed at determining the number of LM cases with cutaneous involvement in the U.S., with the following highlights:","length":246,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Claims from diagnostic codes that are recommended for use with LM patients by the Vascular Anomalies Special Interest Group of the American Society of Pediatric Hematologist Oncologists were rigorously analyzed by a multi-disciplinary resea...